Norda ASA Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2012
August 29, 2012 at 04:08 am
Share
Norda ASA announced unaudited earnings results for the second quarter and six months ended June 30, 2012. For the quarter, the company reported total operating revenues of NOK 238,000 compared with NOK 253,000 for the same period a year ago. LBITDA was NOK 3,346,000 compared with NOK 1,518,000 for the same period a year ago. LBIT was NOK 3,371,000 compared with NOK 1,531,000 for the same period a year ago. Loss before tax and continuing operations was NOK 3,703,000 compared with NOK 2,800,000 for the same period a year ago. Profit attributable to equity holders of the company was NOK 20,561,000 or NOK 7.3 per diluted share compared with loss attributable to equity holders of the company of NOK 12,728,000 or NOK 18.6 per diluted share for the same period a year ago. Net cash used in operating activities was NOK 18,164,000 compared with NOK 9,085,000 for the same period a year ago.
For the six months, the company reported total operating revenues of NOK 453,000 compared with NOK 520,000 for the same period a year ago. LBITDA was NOK 4,940,000 compared with NOK 2,943,000 for the same period a year ago. LBIT was NOK 4,990,000 compared with NOK 2,966,000 for the same period a year ago. Loss before tax and continuing operations was NOK 5,483,000 compared with NOK 5,033,000 for the same period a year ago. Profit attributable to equity holders of the company was NOK 12,965,000 or NOK 4.6 per diluted share compared with loss attributable to equity holders of the company of NOK 24,696,000 or NOK 36.0 per diluted share for the same period a year ago. Net cash used in operating activities was NOK 24,317,000 compared with NOK 21,389,000 for the same period a year ago.
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Companyâs products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
NORDA ASA 